--- title: "Tectonic Therapeutic (TECX) news: offering" url: "https://aibio.space/companies/tectonic-therapeutic/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "TECX offering news: Tectonic cites $159 million cash runway, then agrees to $185.0 million private placement. Tectonic Therapeutic, Inc." --- TECX Tectonic Therapeutic, Inc. NASDAQ · United States # Tectonic Therapeutic (TECX) news TECX offering news Financings · 2025-01-30 ## [Tectonic cites $159 million cash runway, then agrees to $185.0 million private placement](https://aibio.space/news/tectonic-cites-159-million-cash-runway-then-agrees-185-0-million/) Tectonic's January 30, 2025 presentation put cash at $159 million as of September 30, 2024. On February 3 it agreed to a $185.0 million PIPE, with 3,689,465 shares sold at $50.00 each to funds and $54.14 each to officers and directors. ## Latest Tectonic Therapeutic news We have not published a story on Tectonic Therapeutic yet. When there is news, it will appear here. ## Tectonic Therapeutic at a glance - **Ticker**: TECX - **Listing**: NASDAQ - **Country**: United States - **Cash, Jun 30, 2026**: $227.1 million ### Related companies - [Celularity](https://aibio.space/companies/celularity/) NASDAQ: CELU - [Lantheus Holdings](https://aibio.space/companies/lantheus/) NASDAQ: LNTH - [Organogenesis Holdings](https://aibio.space/companies/organogenesis/) NASDAQ: ORGO - [Nutriband](https://aibio.space/companies/nutriband/) NASDAQ: NTRB - [MiMedx Group](https://aibio.space/companies/mimedx/) NASDAQ: MDXG - [CervoMed](https://aibio.space/companies/cervomed/) NASDAQ: CRVO - [Anika Therapeutics](https://aibio.space/companies/anika-therapeutics/) NASDAQ: ANIK - [Valion Bio](https://aibio.space/companies/valion-bio/) NASDAQ: VBIO ### Also on NASDAQ - [QT IMAGING HOLDINGS, INC.](https://aibio.space/companies/qt-imaging/) QTI - [Ardelyx](https://aibio.space/companies/ardelyx/) ARDX - [Neuphoria Therapeutics](https://aibio.space/companies/neuphoria-therapeutics/) NEUP - [Praxis Precision Medicines](https://aibio.space/companies/praxis-precision-medicines/) PRAX - [NewAmsterdam Pharma Company](https://aibio.space/companies/newamsterdam-pharma-n-v/) NAMS - [MacroGenics](https://aibio.space/companies/macrogenics/) MGNX ## What Tectonic Therapeutic does Tectonic Therapeutic is a clinical-stage biotechnology company focused on discovering and developing therapeutic proteins and antibodies that modulate G-protein coupled receptors (GPCRs). It uses a proprietary technology platform called GEODe, short for GPCRs Engineered for Optimal Discovery, to address the historical difficulty of drugging GPCRs with biologics. It focuses on areas of significant unmet medical need, often where therapeutic options are poor or nonexistent. Its lead asset, TX45, is an Fc-relaxin fusion molecule for Group 2 PH-HFpEF and Group 3 PH-ILD, the latter being pulmonary hypertension associated with interstitial lung disease. The TX45 APEX Phase 2 trial in Group 2 PH-HFpEF patients is ongoing. TX2100 is in a Phase 1a clinical trial in healthy volunteers. The company notes that greater than 30% of all approved drugs address GPCR targets, and that the vast majority of those drugs are small molecules whose targets are largely confined to a few GPCR subfamilies. | Product or program | What it is | Stage | |---|---|---| | TX45 | Fc-relaxin fusion molecule for Group 2 PH-HFpEF and Group 3 PH-ILD | Phase 2 (APEX trial ongoing in Group 2 PH-HFpEF) | | TX2100 | Candidate in a clinical trial in healthy volunteers | Phase 1a | | GEODe platform | Proprietary platform for discovering GPCR-targeted therapeutic proteins and antibodies | | Summarised from the company's [10-K filed Feb 26, 2026](https://www.sec.gov/Archives/edgar/data/1681087/000119312526076793/tecx-20251231.htm). ## Tectonic Therapeutic annual financials | Line | FY2025 | FY2024 | |---|---|---| | Research and development | [$63.5 million](https://www.sec.gov/Archives/edgar/data/1681087/000119312526076793/) | [$41.4 million](https://www.sec.gov/Archives/edgar/data/1681087/000119312526076793/) | | Net income (loss) | [-$74.2 million](https://www.sec.gov/Archives/edgar/data/1681087/000119312526076793/) | [-$58.0 million](https://www.sec.gov/Archives/edgar/data/1681087/000119312526076793/) | | Cash from operations | [-$60.1 million](https://www.sec.gov/Archives/edgar/data/1681087/000119312526076793/) | [-$59.1 million](https://www.sec.gov/Archives/edgar/data/1681087/000119312526076793/) | | Cash and equivalents | [$253.8 million](https://www.sec.gov/Archives/edgar/data/1681087/000119312526338062/) | [$141.2 million](https://www.sec.gov/Archives/edgar/data/1681087/000119312526076793/) | Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $227.1 million. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about Tectonic Therapeutic Has Tectonic Therapeutic raised money recently? Our latest story on this, dated Jan 30, 2025: "Tectonic cites $159 million cash runway, then agrees to $185.0 million private placement". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/tectonic-cites-159-million-cash-runway-then-agrees-185-0-million/). What is the ticker symbol of Tectonic Therapeutic? Tectonic Therapeutic, Inc. trades under the ticker TECX on NASDAQ. Where is Tectonic Therapeutic listed? Tectonic Therapeutic, Inc. is listed on NASDAQ. What is the SEC CIK of Tectonic Therapeutic? The SEC Central Index Key (CIK) for Tectonic Therapeutic, Inc. is 1681087. Its filings are on SEC EDGAR. How many shares does Tectonic Therapeutic have outstanding? 19,549,366 shares as of 2026-07-31, per the cover page of its 10-Q filed 2026-08-06. Which country or territory is Tectonic Therapeutic listed under? Our directory records Tectonic Therapeutic, Inc. under United States. What does Tectonic Therapeutic do? Our directory classifies Tectonic Therapeutic, Inc. as: Biopharma / pharmaceuticals. This is a directory classification, not a description of the pipeline. What is the ISIN of Tectonic Therapeutic? The ISIN recorded for Tectonic Therapeutic, Inc. is US8789721086. Does aibio.space cover Tectonic Therapeutic? aibio.space lists Tectonic Therapeutic, Inc. among 2,820 public biotech companies and publishes its news here as stories appear. Where is Tectonic Therapeutic incorporated? SEC records list its state or country of incorporation as NY. What does Tectonic Therapeutic develop? Tectonic Therapeutic is a clinical-stage biotechnology company focused on discovering and developing therapeutic proteins and antibodies that modulate G-protein coupled receptors (GPCRs). It uses a proprietary technology platform called GEODe, short for GPCRs Engineered for Optimal Discovery, to address the historical difficulty of drugging GPCRs with biologics. What is TX45 from Tectonic Therapeutic? TX45: Fc-relaxin fusion molecule for Group 2 PH-HFpEF and Group 3 PH-ILD Stage: Phase 2 (APEX trial ongoing in Group 2 PH-HFpEF). What is TX2100 from Tectonic Therapeutic? TX2100: Candidate in a clinical trial in healthy volunteers Stage: Phase 1a. Is Tectonic Therapeutic profitable? Tectonic Therapeutic, Inc. reported a net loss of $74.2 million for the fiscal year ended Dec 31, 2025, and used $60.1 million of cash in operations, per its annual report to the SEC. How much does Tectonic Therapeutic spend on research and development? $63.5 million in the fiscal year ended Dec 31, 2025, per its annual report. ## Investor discussion: Tectonic Therapeutic Members talk about Tectonic Therapeutic (TECX). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Tectonic Therapeutic, newest first. Each line links the filing it comes from. 1. 2025-01-30 Financings Reported a financing. SEC Form 8-K (Items 7.01,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1681087/000119312525016224/d817477dex991.htm) 2. 2025-01-13 Financings Reported a financing. SEC Form 8-K (Items 7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1681087/000119312525005304/d915399dex991.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:TECX on TradingView](https://www.tradingview.com/symbols/NASDAQ-TECX/). ## SEC filings and registration - **SEC name**: Tectonic Therapeutic, Inc. - **CIK**: 1681087 - **Industry (SIC)**: Biological Products, (No Diagnostic Substances) (2836) - **US tickers**: TECX (Nasdaq) - **State or country of incorporation**: NY - **Fiscal year ends**: December 31 - **Filer category**: Non-accelerated filer
Smaller reporting company - **Business address**: 490 ARSENAL WAY, WATERTOWN, MA - **Phone**: (339) 666-3320 - **Shares outstanding**: 19,549,366 as of 2026-07-31 (10-Q filed 2026-08-06) - **Former names**: AvroBio, Inc.; AVROBIO, Inc. ### Recent filings (8-K and 6-K are the company's own announcements) - [8-K](https://www.sec.gov/Archives/edgar/data/1681087/000119312526407823/d20857d8k.htm) filed 2026-09-29 - [10-Q](https://www.sec.gov/Archives/edgar/data/1681087/000119312526338062/tecx-20260630.htm) filed 2026-08-06 - [8-K](https://www.sec.gov/Archives/edgar/data/1681087/000119312526338000/d114671d8k.htm) filed 2026-08-06 - [8-K](https://www.sec.gov/Archives/edgar/data/1681087/000119312526266040/d124600d8k.htm) filed 2026-06-10 - [8-K](https://www.sec.gov/Archives/edgar/data/1681087/000119312526212069/tecx-20260507.htm) filed 2026-05-07 - [10-Q](https://www.sec.gov/Archives/edgar/data/1681087/000119312526212016/tecx-20260331.htm) filed 2026-05-07 - [DEF 14A](https://www.sec.gov/Archives/edgar/data/1681087/000119312526177467/d54807ddef14a.htm) filed 2026-04-24 - [8-K](https://www.sec.gov/Archives/edgar/data/1681087/000119312526173829/d150495d8k.htm) filed 2026-04-23 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001681087), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details Tectonic Therapeutic, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker TECX, recorded under United States. The directory classifies it as Biopharma / pharmaceuticals. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Tectonic Therapeutic, Inc. - **Ticker**: TECX - **Listing**: NASDAQ - **Country or territory**: United States - **Business scope**: Biopharma / pharmaceuticals - **ISIN**: US8789721086 - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-TECX/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/tectonic-therapeutic/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Tectonic Therapeutic (TECX) news: offering", 2026-10-31, https://aibio.space/companies/tectonic-therapeutic/